Reports Q4 revenue $7.2M, consensus $14.32M. “Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators on our clinical development strategy for the ornithine transcarbamylase (OTC) deficiency program, and to initiating our Phase 2, 12-week cystic fibrosis (CF) study in the first half of 2026,” said Joseph Payne, President & CEO of Arcturus. “We remain firmly committed to advancing our once-daily inhaled mRNA therapy for people with cystic fibrosis Class I mutations.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Options Volatility and Implied Earnings Moves Today, March 03, 2026
- ARCT Earnings this Week: How Will it Perform?
- Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
- Arcturus Therapeutics initiated with a Buy at Roth Capital
- Arcturus Therapeutics price target lowered to $7 from $9 at Citi